Consistency Matters: Clopidogrel Monotherapy as Long-term Secondary Prevention Following Percutaneous Coronary Intervention

Key Points

• This research focuses on the effectiveness of clopidogrel monotherapy for long-term prevention of cardiovascular events after percutaneous coronary intervention.
• Randomized trial design assessing long-term outcomes
• Included patients who underwent percutaneous coronary intervention
• Evaluated the impact of clopidogrel monotherapy on secondary prevention
• Clopidogrel monotherapy significantly reduced cardiovascular event rates in the long term, with a hazard ratio of 0.75, 95% CI 0.65-0.85, p<0.001.
• Reduced rates of major adverse cardiovascular events compared to dual antiplatelet therapy.